SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
The deal to merge into Recursion caps off a tumultuous year for Exscientia, which uses AI to aid drug discovery. (asbe/iStock/Getty Images Plus) After a year defined by pipeline cuts, the departure of ...
Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
"For 2026, we are maintaining our cash operating expense guidance of less than $390 million." (CFO & President of Recursion UK Taylor). "We expect multiple clinical readouts over the next 12 to 18 ...
Algorithms give computers step-by-step instructions to complete tasks accurately.Good algorithms improve software speed, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results